• 16762 Citations
  • 43 h-Index
1979 …2018
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 61 Similar Profiles
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Pemetrexed Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Cisplatin Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Survival Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1979 2018

  • 16762 Citations
  • 43 h-Index
  • 227 Article
  • 5 Review article
  • 2 Chapter
  • 2 Comment/debate
23 Citations

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: Pooled data from two phase II trials

Goss, G., Tsai, C. M., Shepherd, F. A., Ahn, M. J., Bazhenova, L., Crinò, L., de Marinis, F., Felip, E., Morabito, A., Hodge, R., Cantarini, M., Johnson, M., Mitsudomi, T., Jänne, P. A. & Yang, J. C. H., Mar 1 2018, In : Annals of Oncology. 29, 3, p. 687-693 7 p., mdx821.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Central Nervous System
Neoplasm Metastasis
Confidence Intervals
Disease-Free Survival
1 Citations

Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells

Del Re, M., Arrigoni, E., Restante, G., Passaro, A., Rofi, E., Crucitta, S., De Marinis, F., Di Paolo, A. & Danesi, R., Jan 1 2018, (Accepted/In press) In : Stem Cells.

Research output: Contribution to journalArticle

Neoplastic Stem Cells
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Tumor Biomarkers
Drug Resistance
3 Citations

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC

Gadgeel, S., Shaw, A. T., Barlesi, F., Crinò, L., Yang, J. C. H., Dingemans, A. M. C., Kim, D. W., De Marinis, F., Schulz, M., Liu, S., Gupta, R., Kotb, A. & Ou, S. H. I., Jan 1 2018, In : British Journal of Cancer. 118, 1, p. 38-42 5 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Nervous System
Central Nervous System
Incidence
Central Nervous System Diseases
3 Citations

Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients

Garassino, M. C., Gelibter, A. J., Grossi, F., Chiari, R., Soto Parra, H., Cascinu, S., Cognetti, F., Turci, D., Blasi, L., Bengala, C., Mini, E., Baldini, E., Quadrini, S., Ceresoli, G. L., Antonelli, P., Vasile, E., Pinto, C., Fasola, G., Galetta, D., Macerelli, M. & 3 othersGiannarelli, D., Lo Russo, G. & de Marinis, F., Aug 1 2018, In : Journal of Thoracic Oncology. 13, 8, p. 1146-1155 10 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Neoplasms
nivolumab
Population Control
Survival
Non-Small Cell Lung Carcinoma
Immunotherapy
docetaxel
Therapeutics
Pemetrexed